Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORSYYN: CHF 1535 vs Symbicort in COPD
NCT03888131Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jul 2018
- Primary completion
- May 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of beclometasone dipropionate + formoterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Change From Baseline in Pre-dose Morning First Expiratory Volume in 1 Second (FEV1) at 24 weeks. Started Jul 2018; status: completed.
02
Drugs
beclometasone dipropionate + formoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03888131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03888131.